UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G/A
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 3)*
MEDIMMUNE, INC.
---------------------------------------------------------------
(Name of Issuer)
COMMON STOCK, PAR VALUE $.01 PER SHARE
---------------------------------------------------------------
(Title of Class of Securities)
584699102
--------------------------
(CUSIP Number)
----------------------------------------------------------------------
(Date of Event Which Requires Filing This Statement)
Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
[ ] Rule 13d-1(b)
[X] Rule 13d-1(c)
[ ] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be
deemed to be "filed " for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
Page 1 of 6 pages
CUSIP No. 584699102
---------------------------------------------------------------------------------------
1. Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).
BB BIOTECH AG
---------------------------------------------------------------------------------------
2. Check the Appropriate Box if a Member of a Group (See
Instructions)
(a) [X]
(b) []
---------------------------------------------------------------------------------------
3. SEC Use Only
---------------------------------------------------------------------------------------
4. Citizenship or Place of Organization
SWITZERLAND
---------------------------------------------------------------------------------------
Number of 5. Sole Voting Power
Shares Beneficially -0-
Owned by Each
Reporting ---------------------------------------------------------------
Person With:
6. Shared Voting Power
13,125,875
---------------------------------------------------------------
7. Sole Dispositive Power
-0-
---------------------------------------------------------------
8. Shared Dispositive Power
13,125,875
---------------------------------------------------------------------------------------
9. Aggregate Amount Beneficially Owned by Each Reporting Person
13,125,875
10. Check if the Aggregate Amount in Row (11) Excludes Certain shares
11. Percent of Class Represented by amount in Row (11)
5.3%
---------------------------------------------------------------------------------------
12. Type of Reporting Person (See Instructions) HC, CO
---------------------------------------------------------------------------------------
Page 2 of 6 pages
CUSIP No. 584699102
---------------------------------------------------------------------------------------
1. Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).
BIOTECH FOCUS N.V.
---------------------------------------------------------------------------------------
2. Check the Appropriate Box if a Member of a Group (See
Instructions)
(a) [X]
(b) []
---------------------------------------------------------------------------------------
3. SEC Use Only
---------------------------------------------------------------------------------------
4. Citizenship or Place of Organization
Netherlands Antilles
---------------------------------------------------------------------------------------
Number of 5. Sole Voting Power
Shares Beneficially -0-
Owned by Each
Reporting ---------------------------------------------------------------
Person With:
6. Shared Voting Power
13,125,875
---------------------------------------------------------------
7. Sole Dispositive Power
-0-
---------------------------------------------------------------
8. Shared Dispositive Power
13,125,875
---------------------------------------------------------------------------------------
9. Aggregate Amount Beneficially Owned by Each Reporting Person
13,125,875
10. Check if the Aggregate Amount in Row (11) Excludes Certain shares
11. Percent of Class Represented by amount in Row (11)
5.3%
---------------------------------------------------------------------------------------
12. Type of Reporting Person (See Instructions) CO
---------------------------------------------------------------------------------------
Page 3 of 6 pages
CUSIP No. 584699102
-------------------------------------------------------------------------------
ITEM 2.
(a) Name of Person Filing
BB Biotech AG ("BB Biotech")
Biotech Focus N.V. ("Biotech Focus")
(b) Address of Principal Business Office or, if none, Residence
BB Biotech Biotech Focus
Vordergasse 3 De Ruyterkade 62, Willemstad
8200 Schaffhausen Curacao
CH/Switzerland Netherlands Antilles
(c) Citizenship
See Item No. 4 of cover pages.
(d) Title of Class of Securities
Common Stock, Par Value $.01 Per Share
(e) CUSIP Number
584699102
ITEM 4. OWNERSHIP
Provide the following information regarding the aggregate number and
percentage of the class of securities of the issuer identified in Item 1.
(a) Amount beneficially owned:
13,125,875
(b) Percent of class:
5.3%
(c) Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote
-0-
(ii) Shared power to vote or to direct the vote
13,125,875
(iii) Sole power to dispose or to direct the disposition of
-0-
(iv) Shared power to dispose or to direct the disposition of
13,125,875
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED
THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY
This statement is filed jointly by BB Biotech and Biotech Focus. Biotech
Focus is a wholly-owned subsidiary of BB Biotech.
Page 4 of 6 pages
CUSIP No. 584699102
-------------------------------------------------------------------------------
Item 10. Certification
By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were not acquired and are not held
for the purpose of or with the effect of changing or influencing the control
of the issuer of the securities and were not acquired and are not held in
connection with or as a participant in any transaction having that purpose or
effect.
SIGNATURES
After reasonable inquiry and the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
BB BIOTECH AG
Date: February 14, 2002 By: /s/ CATHY BRUGGER
--------------------------
Name: Cathy Brugger
Title: Signatory Authority
Date: February 14, 2002 By: /s/ RUBINO DI GIROLAMO
--------------------------
Name: Rubino Di Girolamo
Title: Signatory Authority
BIOTECH FOCUS N.V.
Date: February 14, 2002 By: /s/ JAN BOOTSMA
--------------------------
Name: Jan Bootsma
Title: Signatory Authority
Date: February 14, 2002 By: /s/ RUBINO DI GIROLAMO
--------------------------
Name: Rubino Di Girolamo
Title: Signatory Authority
Page 5 of 6 pages
CUSIP No. 584699102
-------------------------------------------------------------------------------
EXHIBIT INDEX
-------------
Exhibit 1: Agreement by and between BB Biotech and Biotech Focus with respect
to the filing of this disclosure statement.*
---------------------
* Previously filed.
Page 6 of 6 pages